New Autism Drug Advances to Phase 3 Trials
The investigational drug L1-79 may provide a new option for individuals with autism to address core neurological symptoms.
Updated on Oct. 26, 2026 in Autism
Live Poll
Should the FDA prioritize approving drugs that target the underlying neurological core features of autism?
Yamo Pharmaceuticals is advancing its investigational drug, L1-79, to Phase 3 clinical trials following a successful Phase 2 study. The drug, which has received FDA Fast Track designation, aims to treat core neurological symptoms of autism in the United States.
Why it matters
L1-79 is designed to address core symptoms of autism spectrum disorder, potentially offering a new treatment pathway beyond currently approved medications like aripiprazole and risperidone. Researchers aim to use the drug to balance hyperactive chemical pathways that contribute to sensory overload and social withdrawal.
Phase 2 clinical trials for L1-79 involved 116 patients to evaluate the drug's potential in managing core neurological features of autism. The results of this preliminary study led the company to advance into a 16-week randomized, double-blind Phase 3 treatment period.
The players
Yamo Pharmaceuticals
A privately held pharmaceutical company founded in 2015 that focuses on developing treatments for autism spectrum disorder.
FDA
The federal agency responsible for regulating pharmaceuticals and granting Fast Track designation to expedite the development of drugs for serious conditions.
The details
L1-79 functions as a selective inhibitor of tyrosine hydroxylase, which is an enzyme involved in the synthesis of dopamine and norepinephrine. By reducing the production of these chemicals, the drug seeks to calm hyperactive pathways in the brain. This mechanism is intended to mitigate sensory overload and social withdrawal, which are core features of autism spectrum disorder.
Timeline
December 2026: Yamo Pharmaceuticals will meet with the FDA to finalize Phase 3 protocols.
Early 2027: The Phase 3 clinical trial is expected to begin.
Health Landscape
The development of L1-79 occurs within a landscape where current FDA-approved medications for autism, such as aripiprazole and risperidone, primarily manage associated symptoms rather than core neurological features. If successful, this drug may become the first FDA-approved therapy specifically targeting the core behavioral and neurological manifestations of autism.
Patients and families interested in new developments for autism management should note that L1-79 is currently in the investigational phase and not yet available for clinical use. It is a topic worth discussing with a primary care physician or neurologist to stay informed about clinical trial eligibility and future treatment options.
The takeaway
L1-79 represents a potential shift toward addressing the underlying neurological pathways of autism rather than just associated symptoms. Families can monitor the progress of upcoming clinical trials and should consult their physician about current FDA-approved options for managing specific autism-related symptoms.
What happens next
Yamo Pharmaceuticals is scheduled to meet with the FDA in December 2026 to finalize the protocols for its Phase 3 clinical trial, with patient testing expected to commence in early 2027.
Further reading
For more information on the current state of care, visit Autism.
Source note: This article includes information reported by Mail Online.
Live Poll
Should the FDA prioritize approving drugs that target the underlying neurological core features of autism?
